The role of extended lymph node dissection in patients undergoing radical cystectomy.
Victoria S DawsonMriganka Mani SinhaJulian SmithBhaskar Kumar SomaniJames DouglasPublished in: Turkish journal of urology (2020)
Radical cystectomy (RC) with a pelvic lymph node dissection (LND) is the gold standard for the treatment of muscle invasive bladder cancer (MIBC) as well as for some high-risk non-muscle invasive bladder cancers. The therapeutic advantage of LND, in terms of cancer-specific survival (CSS), still divides opinion and, certainly, the question of the extent of LND at the time of cystectomy is still debated. In this article, we have reviewed the evidence supporting the practice of extending LND in order to help clinicians determine what is appropriate in their practice. There still remains a lack of prospective randomized studies addressing whether extended LND provides a survival benefit in patients undergoing RC for BC. However, there is large body of evidence that suggests there is a positive impact on the oncological outcomes in these patients without an apparent cost of unacceptable adverse events.
Keyphrases
- patients undergoing
- rectal cancer
- robot assisted
- radical prostatectomy
- end stage renal disease
- muscle invasive bladder cancer
- primary care
- healthcare
- lymph node
- ejection fraction
- newly diagnosed
- chronic kidney disease
- sentinel lymph node
- spinal cord injury
- locally advanced
- palliative care
- skeletal muscle
- open label
- free survival
- quality improvement
- double blind
- papillary thyroid
- early stage
- peritoneal dialysis
- prognostic factors
- type diabetes
- squamous cell carcinoma
- clinical trial
- randomized controlled trial
- minimally invasive
- magnetic resonance
- young adults
- combination therapy
- insulin resistance
- phase iii